Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

120
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
120
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

177
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
177
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

123
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
123
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

128
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
128
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

172
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
172

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing human ovarian biology in tandem with clinical care: considerations for collecting ovarian tissue for research after oophorectomy for tissue cryopreservation.

Frontiers in endocrinology·2026
Same author

Following the mobile genome: plasmids as a missing layer in surveillance of carbapenemase-producing Enterobacterales.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same author

Safety and efficacy of faecal microbiota transplantation in Parkinson's disease.

NPJ Parkinson's disease·2026
Same author

A decade of <i>Streptococcus pneumoniae</i> bloodstream infections: a single-center retrospective analysis.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2026
Same author

Surveillance of carbapenemase-producing organisms - considering the practical and local implications of current surveillance processes.

The Journal of hospital infection·2026
Same author

Impact of a Perinatal Psychiatry Access Program on Patient Experience: A Cross-Sectional Study.

Psychiatric services (Washington, D.C.)·2026
Same journal

Peptidomics in the Spotlight: Advanced Sample Treatment Techniques and Analytical Insights.

Advances in experimental medicine and biology·2026
Same journal

Methods for the Investigation of Protein-Ligands Interactions.

Advances in experimental medicine and biology·2026
Same journal

Sample Preparation Strategies for Microbial Cell Surface Proteomics: Integrating Shaving and Shotgun Approaches.

Advances in experimental medicine and biology·2026
Same journal

Proteomic Sample Preparation for the Petroleum Industry: A Biocorrosion Case Study.

Advances in experimental medicine and biology·2026
Same journal

Proteomic and Functional Comparison of Extracellular Vesicles from Wild-Type and Lyn-Deficient Stromal Cells.

Advances in experimental medicine and biology·2026
Same journal

Proteomic Analysis of Histone Sequence Variants and Post-translationally Modified Forms.

Advances in experimental medicine and biology·2026
See all related articles

Related Experiment Video

Updated: Jul 6, 2025

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.0K

European Practice for CDI Treatment.

Fidelma Fitzpatrick1,2, Robert Brennan3, Joffrey van Prehn4

  • 1Department of Clinical Microbiology, The Royal College of Surgeons in Ireland, Dublin, Ireland. fidelmafitzpatrick@rcsi.ie.

Advances in Experimental Medicine and Biology
|January 4, 2024
PubMed
Summary
This summary is machine-generated.

Metronidazole is no longer recommended for Clostridioides difficile infection (CDI) treatment. Fidaxomicin is now preferred due to lower recurrence rates, with vancomycin as an alternative, and new options for recurrent CDI emerging.

Keywords:
Anti-CDI agentsC. difficile prophylaxisC. difficile treatmentCDI guidelinesNovel C. difficile agents

More Related Videos

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.5K
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

38.8K

Related Experiment Videos

Last Updated: Jul 6, 2025

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.0K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.5K
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

38.8K

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Clinical Practice

Background:

  • Clostridioides difficile infection (CDI) is a major global health concern causing significant illness and death.
  • Current treatment options include metronidazole, vancomycin, and fidaxomicin, with metronidazole showing lower efficacy.
  • The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) updated CDI management guidelines in 2021.

Purpose of the Study:

  • To assess current European practices in managing Clostridioides difficile infection (CDI).
  • To evaluate the adoption and implementation of the 2021 ESCMID CDI management guidelines.
  • To identify variations in CDI treatment strategies and pre-prescription requirements across European countries.

Main Methods:

  • A survey was conducted in November 2022, with 64 respondents from 17 European countries.
  • The survey assessed the existence of national CDI guidelines and the incorporation of the 2021 ESCMID guidance.
  • Data were collected on first-line treatment choices, use of agents in high-risk patients, and pre-prescription approval processes.

Main Results:

  • Vancomycin (66%) and fidaxomicin (47%) are the most common first-line treatments for CDI, while metronidazole use has decreased.
  • Fidaxomicin is more frequently used for high-risk patients.
  • Pre-prescription approval is common for newer agents like bezlotoxumab and fecal microbiota transplantation (FMT).

Conclusions:

  • European CDI management is evolving, with a shift away from metronidazole towards fidaxomicin and vancomycin.
  • Implementation of updated guidelines is progressing, but variations in practice and restrictions persist.
  • Novel therapies and FMT show promise for recurrent CDI, though their roles are still under evaluation.